• Publications
  • Influence
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
UNLABELLED Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remainsExpand
  • 115
  • 8
Late-Onset Neutropenia After Rituximab Treatment: Case Series and Comprehensive Review of the Literature
Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma. Recently, its use has been expanded to include treatment of otherExpand
  • 116
  • 4
How I treat mixed-phenotype acute leukemia.
Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms andExpand
  • 80
  • 3
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Thrombosis in myeloproliferative neoplasms is associated with increased NETosis that can be targeted with JAK inhibitors. A NET increase in thrombosis Excessive thrombosis is a major cause ofExpand
  • 78
  • 3
Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato‐oncological patients: Randomized controlled trial
Intravenous (IV) granulocyte colony stimulating factor (G‐CSF) might be safer and more convenient than subcutaneous (SC) administration to hospitalized hemato‐oncological patients receivingExpand
  • 11
  • 2
Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
Background:The importance of telomerase in multiple myeloma (MM) is well established; however, its response to bortezomib has not been addressed.Methods:The effect of bortezomib on telomeraseExpand
  • 12
  • 2
Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia
Blinatumomab is a CD19/CD3 bispescific antibody designed to redirect T cells toward malignant B cells and induce their lysis. It recently gained accelerated approval by the FDA for the treatment ofExpand
  • 15
  • 2
Lymphoma and Leukemia Cells Possess Fractal Dimensions That Correlate with Their Biological Features
Background: Living cells can be viewed as complex adaptive systems that exhibit non-linear dynamics and fractal features. We investigated the fractal qualities of normal and malignant hematologicalExpand
  • 52
  • 1
Neutropenia after rituximab treatment: new insights on a late complication
Purpose of reviewLate-onset neutropenia (LON) after rituximab administration may be encountered in various clinical settings. The identification of neutropenia after rituximab treatment may haveExpand
  • 52
  • 1
Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression
Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency characterized by the absence or malfunction of the NADPH oxidase in phagocytic cells. As a result, there is an impairedExpand
  • 60
  • 1